In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Marker Therapeutics (MRKR – Research Report), with a price target of $8.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
John Newman has given his Buy rating due to a combination of factors related to Marker Therapeutics’ strategic collaborations and promising clinical developments. The partnership with Cellipont to manufacture MT-601 is seen as a strategic move that could enhance production efficiency and reduce regulatory risks, which is crucial for the success of pivotal studies and potential commercialization. Cellipont’s ability to scale up production once MT-601 is approved is another significant advantage, as it mitigates the challenges associated with tech transfer in the complex field of cell therapy manufacturing.
Additionally, John Newman anticipates positive updates from the MT-601 APOLLO study in the second half of 2025, expecting improved efficacy and a larger patient cohort. The initial results have already shown promising response and remission rates in B-cell lymphoma patients who had limited options. These factors, combined with the potential for future expansion in treating other cancers, underpin the Buy rating and the $8 price target for MRKR.
According to TipRanks, Newman is an analyst with an average return of -6.0% and a 33.94% success rate. Newman covers the Healthcare sector, focusing on stocks such as BioNTech SE, Marker Therapeutics, and Regeneron.